Trials / Completed
CompletedNCT04352114
A Study of LY3461767 in Healthy Participants
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3461767 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3461767 and any side effects that might be associated with it. The study will also measure how much LY3461767 gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last about 11 weeks, including screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3461767 - SC | Administered SC. |
| DRUG | LY3461767 - IV | Administered IV. |
| DRUG | Placebo - SC | Administered SC. |
Timeline
- Start date
- 2020-06-15
- Primary completion
- 2021-01-13
- Completion
- 2021-01-13
- First posted
- 2020-04-20
- Last updated
- 2021-02-05
Locations
3 sites across 2 countries: United States, Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04352114. Inclusion in this directory is not an endorsement.